ATE440602T1 - Nicotinrezeptoragonisten in stammzellen und vorlaüferzellinduktion - Google Patents

Nicotinrezeptoragonisten in stammzellen und vorlaüferzellinduktion

Info

Publication number
ATE440602T1
ATE440602T1 AT00952302T AT00952302T ATE440602T1 AT E440602 T1 ATE440602 T1 AT E440602T1 AT 00952302 T AT00952302 T AT 00952302T AT 00952302 T AT00952302 T AT 00952302T AT E440602 T1 ATE440602 T1 AT E440602T1
Authority
AT
Austria
Prior art keywords
stem cells
progressor
receptor agonists
nicotine receptor
cell induction
Prior art date
Application number
AT00952302T
Other languages
English (en)
Inventor
John Cooke
Frances Lauri Johnson
Anjali Pathak
James Jang
Phillip Tsao
Christopher Heeschen
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE440602T1 publication Critical patent/ATE440602T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00952302T 1999-07-28 2000-07-28 Nicotinrezeptoragonisten in stammzellen und vorlaüferzellinduktion ATE440602T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14623399P 1999-07-28 1999-07-28
US18830000P 2000-03-10 2000-03-10
PCT/US2000/020724 WO2001008683A1 (en) 1999-07-28 2000-07-28 Nicotine receptor agonists in stem cell and progenitor cell recruitment

Publications (1)

Publication Number Publication Date
ATE440602T1 true ATE440602T1 (de) 2009-09-15

Family

ID=26843696

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00952302T ATE440602T1 (de) 1999-07-28 2000-07-28 Nicotinrezeptoragonisten in stammzellen und vorlaüferzellinduktion

Country Status (9)

Country Link
US (1) US6720340B1 (de)
EP (1) EP1207879B1 (de)
JP (2) JP2003505506A (de)
AT (1) ATE440602T1 (de)
AU (1) AU778386B2 (de)
BR (1) BR0012787A (de)
CA (1) CA2380052C (de)
DE (1) DE60042828D1 (de)
WO (1) WO2001008683A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838539B2 (en) * 1999-07-28 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University Nicotine receptor agonists in stem cell and progenitor cell recruitment
CA2494506C (en) * 2002-08-02 2009-02-10 Nutraceutical Development Corporation Development of muscle mass in a mammal
TW200605910A (en) 2004-04-30 2006-02-16 Orbus Medical Technologies Inc Medical device with coating for capturing genetically-altered cells and methods for using same
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
AU2006331790A1 (en) * 2005-12-19 2007-07-05 Comentis, Inc. Topical mecamylamine formulations for ocular administration and uses therof
WO2007119240A2 (en) * 2006-04-17 2007-10-25 Hepacore Ltd. Methods for bone regeneration using endothelial progenitor cell preparations
ES2629086T3 (es) * 2006-10-30 2017-08-07 Genomix Co., Ltd. Sustancia farmacéutica para promover la regeneración funcional de tejido dañado
WO2008118370A2 (en) * 2007-03-22 2008-10-02 The Trustees Of The University Of Pennsylvania Hyperbaric treatment in wound healing
US8673580B2 (en) 2008-04-30 2014-03-18 Genomix Co., Ltd. Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation
JP5676253B2 (ja) 2008-04-30 2015-02-25 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
JP5865703B2 (ja) 2009-10-28 2016-02-17 株式会社ジェノミックス 骨髄間葉系および／または多能性幹細胞の血中動員による組織再生促進剤
WO2012048276A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
PT3358011T (pt) 2011-04-26 2020-04-23 Univ Osaka Péptido para induzir a regeneração de um tecido e a sua utilização
US9688733B2 (en) 2012-10-25 2017-06-27 Genomix Co., Ltd. Method for treating spinal cord injury using HMGB1 fragment
ES2660420T3 (es) 2012-10-25 2018-03-22 Genomix Co., Ltd. Método novedoso para tratar infarto cardiaco utilizando fragmento de HMGB1
US10172911B2 (en) 2013-10-01 2019-01-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of modulating erythropoiesis with arginine vasopressin receptor 1B molecules
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
EP3198006B1 (de) 2014-09-26 2021-03-24 Terumo BCT, Inc. Geplante fütterung
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
EP3556378B1 (de) 2017-01-27 2025-03-12 StemRIM Inc. Therapeutisches mittel für kardiomyopathie, alten myokardinfarkt und chronisches herzversagen
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
CN111868231B (zh) 2017-12-01 2024-05-31 斯特姆里姆有限公司 外胚层间充质干细胞及其产生方法
CN111542335A (zh) 2017-12-01 2020-08-14 斯特姆里姆有限公司 炎症性肠病的治疗药
US20210024594A1 (en) 2018-02-08 2021-01-28 StemRIM Inc. Therapeutic Agent for Psoriasis
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
EP4314244B1 (de) 2021-03-23 2025-07-23 Terumo BCT, Inc. Zellerfassung und -erweiterung
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321387A (en) 1980-03-21 1982-03-23 Philip Morris, Incorporated Process for the preparation of optically active nicotine analogs
US4442292A (en) 1981-01-29 1984-04-10 Philip Morris Incorporated Optically active nicotine analogs and process for their preparation
US4332945A (en) 1981-01-29 1982-06-01 Philip Morris, Incorporated Optically active nicotine analogs and process for their preparation
US4452984A (en) 1981-01-29 1984-06-05 Philip Morris, Inc. Optically active nicotine analogs and process for their preparation
US4590278A (en) 1981-01-29 1986-05-20 Philip Morris Incorporated Nicotine analogs
GB8330969D0 (en) 1983-11-21 1983-12-29 Wellcome Found Promoting healing
US4920989A (en) 1985-04-25 1990-05-01 Regents Of The University Of California Method and apparatus for aiding in the reduction of incidence of tobacco smoking
US4943435A (en) 1987-10-05 1990-07-24 Pharmetrix Corporation Prolonged activity nicotine patch
US5318957A (en) 1992-09-02 1994-06-07 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating angiogenesis
US5766948A (en) * 1993-01-06 1998-06-16 The Regents Of The University Of California Method for production of neuroblasts
US5508030A (en) 1993-08-05 1996-04-16 Bierman; Howard R. Creating new capillary blood pools for practicing bidirectional medicine
US5830651A (en) * 1995-06-01 1998-11-03 Signal Pharmaceuticals, Inc. Human oligodendroglial progenitor cell line
WO1997034605A1 (en) * 1996-03-21 1997-09-25 Mayo Foundation For Medical Education And Research Use of nicotine to treat liver disease
US5869037A (en) 1996-06-26 1999-02-09 Cornell Research Foundation, Inc. Adenoviral-mediated gene transfer to adipocytes
US5866561A (en) 1997-08-21 1999-02-02 Scimed Life Systems, Inc. Local delivery of estrogen for angiogenesis
EP1434573A2 (de) * 1998-10-20 2004-07-07 Omeros Corporation Spüllösung und verfahren zur schmerzhinderung und entzündungshemmung

Also Published As

Publication number Publication date
EP1207879B1 (de) 2009-08-26
JP2008291040A (ja) 2008-12-04
AU778386B2 (en) 2004-12-02
JP2003505506A (ja) 2003-02-12
DE60042828D1 (de) 2009-10-08
CA2380052A1 (en) 2001-02-08
AU6502600A (en) 2001-02-19
EP1207879A1 (de) 2002-05-29
BR0012787A (pt) 2002-07-30
EP1207879A4 (de) 2004-05-12
CA2380052C (en) 2007-10-23
US6720340B1 (en) 2004-04-13
WO2001008683A1 (en) 2001-02-08

Similar Documents

Publication Publication Date Title
ATE440602T1 (de) Nicotinrezeptoragonisten in stammzellen und vorlaüferzellinduktion
ATE330972T1 (de) Apo-2l rezeptor-agonist und cpt-11 synergie- effekt
ATE448686T1 (de) Actriib-fusionspolypeptide und verwendungen dafür
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
SG150550A1 (en) Pharmaceutical preparation containing an antibody for the egf receptor
DK1545537T3 (da) Alfa-7-nikotinreceptoragonister og statiner i kombination
CO5450244A1 (es) Derivados de adenina
HUP0203870A2 (hu) Adenozinreceptor agonistát vagy antagonistát tartalmazó gyógyászati készítmény
WO2007087367A3 (en) Methods and compositions for modulating the mobilization of stem cells
BR0016166A (pt) Compostos de diidropirimidina heterocìclicos
AU5811001A (en) Cxcr4 antagonist treatment of hematopoietic cells
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
YU13301A (sh) Muskarinski agonisti i antagonisti
DE60106002D1 (de) Behandlung von hematopoietischen zellen mit cxcr4 agonisten
BR0017338A (pt) Composto, processo para preparar um composto, composição farmacêutica, e métodos para tratar um paciente, para inibir quimiotaxia celular promovida com c5a, para localizar receptores de c5a em um tecido, e para reduzir a gravidade ou frequência de uma ou mais sequelas inflamatórias de transplante de órgão
NO2019032I1 (no) Treosulfan
UA87980C2 (ru) Композиция для улучшения познания и памяти
ATE277639T1 (de) Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten
DE60008590D1 (de) Zusammensetzungen von adenosin a1 agonisten und cox2-hemmern
WO2005079344A3 (en) Nicotine receptor agonists in stem cell and progenitor cell recruitment
BR9913846A (pt) Antagonista receptor de quemocina e ciclosporina em terapia combinada
DE60008589D1 (de) Zusammensetzungen von adenosin a1 agonisten mit 5ht1 agonisten
NO20012169L (no) Forbindelser med veksthormonfrigjörende egenskaper
UA84714C2 (ru) Производные имидазопиридинзамещенного тропана с антагонистической активностью ccr5 рецепторов для лечения вич и воспаления

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties